Optimization of Early Stage Oral Dosing and Drug Development to be Presented at Upcoming Medicinal Chemistry Ireland Conference by Catalent Expert

Share Article

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Pascale Clement, Director of Science and Technology, will be presenting at the upcoming inaugural Medicinal Chemistry Ireland Conference, to be held at Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, on July 1st, 2016.

Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that Dr. Pascale Clement, Director of Science and Technology, will be presenting at the upcoming inaugural Medicinal Chemistry Ireland Conference, to be held at Trinity Biomedical Sciences Institute, Trinity College Dublin, Ireland, on July 1st, 2016.

Dr. Clement’s presentation, at 11.30 a.m., is entitled “Accelerating Oral Drug Development Through Systematic Early Technology Selection,” and will discuss the oral drug development challenges facing the industry, and the benefits of accurate, early stage assessment of compounds’ physicochemical and biopharmaceutical properties to the selection of the right drug candidate form and enabling drug product’s technology. Along with demonstrative case studies, she will discuss the advantages of combining reliable data and a suite of technologies that can optimize bioavailability leading to pharmacologically effective and developable candidates entering the clinic, and ultimately the market, faster.

Dr. Clement joined Catalent in January 2016 as the Director of Science and Technology, bringing extensive experience in pharmaceutical development of multiple dosage forms for NCEs and generic pharmaceutical products. In her role, she is part of the scientific leadership team within Catalent, responsible for its OptiForm® Solution Suite bioavailability enhancement platform, and softgel development for the European market. OptiForm Solution Suite was launched in 2015 to identify the most stable and efficient drug form for small molecules, and it was announced earlier this month that the scope of the platform has now been expanded to encompass macromolecules.

Dr. Clement has over 20 years of formulation and development experience, and has previously held a number of roles at companies including Skyepharma and Pharmascience in Canada, and at HWI Analytik (Germany), where she led a project management and pharmaceutical development team. She holds a Ph.D. in Pharmaceutical Sciences from Paris XI University.

For more information on the Medicinal Chemistry Ireland Conference, visit: https://medchemmeet.wordpress.com/ and to arrange a meeting with Dr. Clement, contact Richard Kerns at NEPR- richard(at)nepr(dot)eu.

About Catalent
Catalent is the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. With over 80 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable clinical and commercial product supply. Catalent employs approximately 8,700 people, including over 1,000 scientists, at 31 facilities across 5 continents, and in fiscal 2015 generated more than $1.8 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit http://www.catalent.com

More products. Better treatments. Reliably supplied.™

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Chris Halling

Richard Kerns
Northern Exposure PR
+44 7974 579202
Email >
Visit website